MYSP-PI-2022-070

欧阳德方


下載導師簡歷CV
Section 1: Personal Particulars

欧阳德方
Defang Ouyang
Associate Professor
2884 1358
88224514
defangouyang@um.edu.mo
ICMS, University of Macau
University of Macau
UMAC-SKL of Quality Research in Chinese Medicine
na
https://sklqrcm.um.edu.mo/de-fang-ouyang/

Research Project provided for Macao Youth Scholars Program:

计算药剂学
Computational pharmaceutics
1007 药学
1008 中药学
Self-motivation and hard-working
PhD
Prof. Ouyang has published 2 books, 5 book chapters and over 70 refereed SCI journal papers. He held 6 approved patents, which had been used in medicinal products. He edited the first book (John Wiley & Sons Inc., 2015) in this research area. He is invited to be the Editors-in-Chief of (Springer Nature) and associate editor of . He also serves as the editorial board or scientific advisor of , , and . He established the first global artificial intelligence (AI)-based formulation platform “FormulationAI” (https://pharmes.computpharm.org/#).

Section 2: Research Interests and Grants

Prof. Ouyang has pioneered the integration of multi-scale modeling, artificial intelligence and big data techniques in the field of drug delivery – “computational pharmaceutics“. • Artificial intelligence (AI) of pharmaceutical formulations: to build the database of pharmaceutical formulations and predict pharmaceutical formulations by machine learning approaches; • Multi-scale modeling in drug delivery: to integrate quantum mechanics (QM), molecular dynamics (MD) and physiologically based pharmacokinetic (PBPK) modeling into drug delivery systems; • Pharmacoinformatics: big data analysis of pharmaceutical information from the literature, patent, clinical trial and marketed products.
4
4
1
Preparation and evaluation of a highly-soluble Ginsenoside Rh2 formulation. FDCT, 0108/2021/A, MOP$721,000.00, 01/2022 - 06/2023;
Prediction of ternary cyclodextrin formulations by machine learning approaches. University of Macau, MYRG2020-00113-ICMS, MOP$360,000.00, 01/2022 - 12/2023;
药物制剂分子模拟平台的构建与验证. 深港澳科技 计划 项目( C 类项目), 批准。